Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Glioma 6Ependymoma 6Central Nervous System Neoplasms 5Sarcoma, Ewing 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lung Neoplasms 3Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2Desmoid Tumors 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Thyroid Cancer, Papillary 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Sarcoma, Synovial 1

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2Ipilimumab 2tazemetostat 1pembrolizumab 1atezolizumab 1X-Rays 1Tiragolumab 1Phantoms, Imaging 1Fluorodeoxyglucose F18 1Cetuximab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chordoma × Phantoms, Imaging × 90 days × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡